852330-31-5

Basic information

• Product Name: Methyl 5-broMo-3-(2,2,2-trifluoroacetaMido)thiophe
• Synonyms: Methyl 5-broMo-3-(2,2,2-trifluoroacetaMido)thiophe;5-BroMo-3-(2,2,2-trifluoro-acetylaMino)-thiophene-2-carboxylicacidMethylester;Methyl 5-broMo-3-(2,2,2-trifluoroacetaMido)thiophene-2-carboxylate
• CAS NO: 852330-31-5
• Molecular Formula: C₈H₅BrF₃NO₃S
• Molecular Weight: 332.0944096
• Mol File: 852330-31-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Methyl 5-broMo-3-(2,2,2-trifluoroacetaMido)thiophe(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 5-broMo-3-(2,2,2-trifluoroacetaMido)thiophe(852330-31-5)
• EPA Substance Registry System: Methyl 5-broMo-3-(2,2,2-trifluoroacetaMido)thiophe(852330-31-5)

Safety Data

• Hazardous Substances Data: 852330-31-5(Hazardous Substances Data)

Usage

General Description

Methyl 5-bromo-3-(2,2,2-trifluoroacetamido)thiophene is a chemical compound that consists of a methyl group, a bromine atom, and a 3-(2,2,2-trifluoroacetamido)thiophene moiety. It is a potentially useful building block for the synthesis of various organic compounds, particularly in the field of pharmaceuticals and agrochemicals. The bromine substituent and trifluoroacetamido group confer unique reactivity and properties to the molecule, making it valuable in organic synthesis. Its structure and reactivity make it a potential candidate for the development of new drugs and agricultural chemicals that may have improved efficacy and other desirable properties. Overall, Methyl 5-bromo-3-(2,2,2-trifluoroacetamido)thiophene is a versatile and valuable chemical compound with potential applications in various fields.

Upstream product

• 79128-68-0 methyl 3-(2,2,2-trifluoroacetamido)thiophene-2-carboxylate 
• 107818-55-3 3-amino-5-bromo-thiophene-2-carboxylic acid methyl ester 
• 407-25-0 trifluoroacetic anhydride 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 

Downstream Products

• 107818-55-3 3-amino-5-bromo-thiophene-2-carboxylic acid methyl ester 
• 1244027-97-1 methyl 5-bromo-3-[(3-nitrobenzyl)amino]thiophene-2-carboxylate 
• 1330783-91-9 benzyl 1-{6-[1-(tert-butoxycarbonyl)-3-methyl-1H-pyrazol-4-yl]-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl}-7-azabicyclo[2.2.1]heptane-7-carboxylate 
• 1330781-99-1 6-(5-methyl-1H-pyrazol-4-yl)-2-(2-phenyl-1-pyrrolidin-1-ylethyl)thieno[3,2-d]pyrimidin-4(3H)-one 
• 1330783-58-8 N-(5-bromo-2-carbamoylthiophen-3-yl)-1-[4-(methylsulfonyl)phenyl]prolinamide 
• 1330783-56-6 6-bromo-2-{1-[4-(methylsulfonyl)phenyl]pyrrolidin-2-yl}thieno[3,2-d]pyrimidin-4(3H)-one 
• 1330781-90-2 6-(5-methyl-1H-pyrazol-4-yl)-2-{1-[4-(methylsulfonyl)phenyl]pyrrolidin-2-yl}thieno[3,2-d]pyrimidin-4(3H)-one 
• 1330783-39-5 6-bromo-2-[phenyl(pyrrolidin-1-yl)methyl]thieno[3,2-d]pyrimidin-4(3H)-one 
• 1330783-38-4 5-bromo-3-{[phenyl(pyrrolidin-1-yl)acetyl]amino}thiophene-2-carboxamide 
• 1330782-88-1 6-bromo-2-(2-chlorophenyl)thieno[3,2-d]pyrimidin-4(3H)-one 
• 1330781-03-7 2-(2-chlorophenyl)-6-(5-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one 
• 1330784-49-0 2-(pyrrolidin-1-ylmethyl)-6-[3-(trifluoromethyl)-1-trityl-1H-pyrazol-4-yl]thieno[3,2-d]pyrimidin-4(3H)-one 
• 1330784-43-4 tert-butyl 2-[(5-bromo-2-carbamoylthiophen-3-yl)carbamoyl]-4-hydroxy-4-phenylpyrrolidine-1-carboxylate 
• 1330784-42-3 tert-butyl 2-{[5-bromo-2-(methoxycarbonyl)thiophen-3-yl]carbamoyl}-4-hydroxy-4-phenylpyrrolidine-1-carboxylate 

Relevant articles and documents

Solid-phase synthetic method for N-alkyl-4-alkylamino-6-arylthieno[3,2-d]pyrimidine-2-carboxamide derivatives

Herein, we describe a solid-phase synthetic method for synthesizing N-alkyl-4-alkylamino-6-arylthieno[3,2-d]pyrimidine-2-carboxamide derivatives. The derivatives consist of the biologically active 6-phenylthieno[3,2-d]pyrimidine scaffold. The template mediated synthetic strategy involving Suzuki coupling reactions between methyl 3-amino-5-bromothiophene-2-carboxylate and arylboronic acids afforded methyl 3-amino-5-arylthiophene-2-carboxylates. Cyclocondensation reactions involving methyl 3-amino-5-arylthiophene-2-carboxylates and methyl cyanoformate afforded esters, that when subjected to hydrolysis reactions yielded 6-aryl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidine-2-carboxylic acids (template compounds). These carboxylic acid templates were coupled with primary alkylamine-loaded acid-sensitive methoxybenzaldehyde (AMEBA) resins. The amide coupling reactions were followed by direct amination reactions mediated by benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP). The compounds were subsequently cleaved from the solid support, purified using the reverse phase-high performance liquid chromatography technique (RP-HPLC), and passed through a strong anion exchange (SAX) resin pretreated with water to yield the N-alkyl-4-alkylamino-6-arylthieno[3,2-d]pyrimidine-2-carboxamide derivatives. The reaction conditions for the solid-phase transformations were optimized using a solution-phase model using 2,4-dimethoxybenzyl-protected isobutylamine as a reactant. 2,4-Dimethoxybenzyl-protected isobutylamine, and not AMEBA resin-loaded isobutylamine was used during the process. Substituent variation experiments were performed using 6-aryl-4-oxo-3,4-dihydrothieno[3,2-d]pyrimidine-2-carboxylic acids and a variety of primary and secondary amine building blocks. Additionally, we could include the Suzuki coupling step in a modified solid-phase synthetic sequence.

THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS

The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer

Thienopyrimidinone bis-aminopyrrolidine ureas as potent melanin-concentrating hormone receptor-1 (MCH-R1) antagonists

A series of thienopyrimidinone bis-aminopyrrolidine ureas were designed, synthesized, and evaluated for their ability to bind melanin-concentrating hormone receptor-1. These compounds exhibit potent binding affinity (Ki = 3 nM) and good in vitro metabolic stability.